Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Bone marrow depression. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-001447-39 Sponsor Protocol Number: AB15003 Start Date*: 2019-10-21
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ...
    Medical condition: Smouldering or Indolent Severe Systemic mastocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001989-36 Sponsor Protocol Number: SIGN Start Date*: 2022-09-07
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial
    Medical condition: gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001706-42 Sponsor Protocol Number: JCAR015-ALL-001 Start Date*: 2016-11-16
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
    Medical condition: B-cell Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000370-20 Sponsor Protocol Number: 2448/2007 Start Date*: 2008-08-05
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Evaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders.
    Medical condition: bipolar disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057667 Bipolar disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004364-35 Sponsor Protocol Number: CETB115AUS01T Start Date*: 2018-07-25
    Sponsor Name:National Heart, Lung, and Blood
    Full Title: Eltrombopag added to standard immunosuppression in treatment-naïve severe aplastic anemia.
    Medical condition: Severe aplastic anemia (SAA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-000972-25 Sponsor Protocol Number: AB06006 Start Date*: 2013-06-06
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety ...
    Medical condition: Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicaps
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026891 Mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Prohibited by CA) GB (Completed) IT (Completed) BG (Completed) HU (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000174-19 Sponsor Protocol Number: 9345 Start Date*: 2015-01-27
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Re...
    Medical condition: Moderate Aplastic Anemia (MAA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001606-14 Sponsor Protocol Number: 2017/2555 Start Date*: 2017-10-10
    Sponsor Name:Gustave Roussy
    Full Title: A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer
    Medical condition: Metastatic Castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003120-17 Sponsor Protocol Number: PDY16963 Start Date*: Information not available in EudraCT
    Sponsor Name:Genzyme Corporation
    Full Title: A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment
    Medical condition: Gaucher disease type 3
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10075699 Gaucher's disease type III PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000304-14 Sponsor Protocol Number: GlioVax Start Date*: 2018-03-06
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma
    Medical condition: newly diagnosed glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002456-88 Sponsor Protocol Number: Stroke34 Start Date*: 2023-02-28
    Sponsor Name:CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E
    Full Title: STROKE34: randomized controlled phase IIa trial of intra-arterial CD34+ cells in acute ischemic stroke.
    Medical condition: Acute ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005345-11 Sponsor Protocol Number: RA2364 Start Date*: 2007-08-08
    Sponsor Name:University of Nottingham
    Full Title: ‘Stem cell Trial of recovery EnhanceMent after Stroke 2’ (STEMS2) pilot randomised placebo-controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acu...
    Medical condition: Ischaemic and Haemorrhagic Stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005259-18 Sponsor Protocol Number: PROUD-PV Start Date*: 2013-08-15
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001771-21 Sponsor Protocol Number: XL184–311 Start Date*: Information not available in EudraCT
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-...
    Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) AT (Prematurely Ended) HU (Completed) ES (Ongoing) PL (Trial now transitioned) CZ (Completed) HR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002662-12 Sponsor Protocol Number: GINECO-EN203b Start Date*: 2020-01-16
    Sponsor Name:ARCAGY-GINECO
    Full Title: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or rec...
    Medical condition: metastatic or recurrent endometrial or ovarian carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000240-34 Sponsor Protocol Number: REX-001-004 Start Date*: 2016-07-07
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: A Multicenter, Randomized, Double-Blind, Placebo Contro...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10077142 Limb ischemia LLT
    19.0 100000004866 10058069 Critical limb ischemia LLT
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) AT (Completed) NL (Ongoing) HU (Completed) PL (Completed) PT (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002499-14 Sponsor Protocol Number: PI2018_843_0051 Start Date*: 2021-05-26
    Sponsor Name:CHU Amiens-Picardie
    Full Title: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a ran...
    Medical condition: diffuse large B cell lymphoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004010-10 Sponsor Protocol Number: UoL001253 Start Date*: 2017-10-20
    Sponsor Name:University of Liverpool
    Full Title: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
    Medical condition: Previously untreated, high tumour burden follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023083-40 Sponsor Protocol Number: SPON830-10 Start Date*: 2012-03-19
    Sponsor Name:Cardiff University
    Full Title: A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse
    Medical condition: Rectal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000670-29 Sponsor Protocol Number: ARIES Start Date*: 2018-06-26
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Avelumab as single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin. The ARIES Study
    Medical condition: metastatic or locally advanced urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 12:04:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA